RANKL, RANK, osteoprotegerin: Key partners of osteoimmunology and vascular diseases

Cellular and Molecular Life Sciences

Volumn 64, Issue 18, 2007, Pages 2334-2350

  Baud'huin, M ^a,b   Lamoureux, F ^a,b   Duplomb, L ^a,b   Redini F ^a,b   Heymann, D ^a,b,c  

^a UNIVERSITÉ DE NANTES   (France)

^b INSERM   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Bone remodeling; Cardiovascular disease; Osteoclast; Osteoimmunology; Osteolysis; Osteoprotegerin; RANKL

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RECEPTOR;

BLOOD VESSEL CALCIFICATION; BONE DISEASE; BONE METABOLISM; BONE REMODELING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; IMMUNITY; KNOCKOUT MOUSE; OSTEOCLAST; OSTEOLYSIS; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; BONE AND BONES; HUMANS; MICE; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; VASCULAR DISEASES;

MUS MUSCULUS;

EID: 34548647431     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-007-7104-0     Document Type: Review

References (207)

1. Dempster, D. W. (2006) Anatomy and functions of the adult skeleton. In: Primer of the Metabolic Bone Diseases and Disorders of Mineral Metabolism, edn 6 (Favus, M. J., Ed.), pp 7-11, American Society for Bone and Mineral Research, Durham.
2. Ross, F. P. (2006) Osteoclast biology and bone resorption. In: Primer of the Metabolic Bone Diseases and Disorders of Mineral Metabolism, edn 6 (Favus, M. J., Ed.), pp. 30-35. American Society for Bone and Mineral Research, Durham.
3. Rousselle, A. V. and Heymann, D. (2002) Osteoclastic acidification during bone resorption. Bone 30, 533-540.
4. Aubin, J. E., Lian, J. B. and Stein, G. S. (2006) Bone formation maturation and functional activities of osteoblast lineage cells. In: Primer of the Metabolic Bone Diseases and Disorders of Mineral Metabolism, edn 6 (Favus, M. J., Ed.), pp. 20-29, American Society for Bone and Mineral Research, Durham.
5. Favus, M. J., Bushinsky, D. A. and Lemann Jr, J. (2006) Regulation of calcium, magnesium, and phosphate metabolism. In: Primer of the Metabolic Bone Diseases and Disorders of Mineral Metabolism, edn 6 (Favus, M. J., Ed.), pp. 76-83, American Society for Bone and Mineral Research, Durham.
6. Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J. and Suda, T. (1988) Osteoblastic cells are involved in osteoclast formation. Endocrinology 123, 2600-2602.
7. Jimi, E., Nakamura, I., Amano, H., Taguchi, Y., Tsurukai, T., Tamura, M., Takahashi, N. and Suda, T. (1996) Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology 137, 2187-2190.
8. Friedman, P. A. and Goodman, W. G. (2006) PTH(1-84)/PTH(7-84): a balance of power. Am., J. Physiol. Renal Physiol. 290, F975-F984.
9. Holick, M. F. (2006) The role of vitamin D for bone health and fracture prevention. Curr. Osteoporos. Rep. 4, 96-102.
10. Findlay, D. M. and Sexton, P. M. (2004) Calcitonin. Growth Factors 22, 217-224.
11. Boyle, W. J., Simonet, W. S. and Lacey, D. L. (2003) Osteoclast differentiation and activation. Nature 423, 337-342.
12. Teitelbaum, S. L. (2007) Osteoclasts: what do they do and how do they do it? Am. J. Pathol. 170, 427-435.
13. Takayanagi, H., Sato, K., Takaoka, A. and Taniguchi, T. (2005) Interplay between interferon and other cytokine systems in bone metabolism. Immunol. Rev. 208, 181-193.
14. Tsuda, E., Goto, M., Michizuki, S., Yano, K., Kobayashi, F., Morinaga, T., Hisgashio, K. (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234, 137-142.
15. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J. and Boyle, W. J. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176.
16. Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S. I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., Kanno, T., Murakami, A., Tsuda, E., Morinaga, T. and Higashio, K. (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139, 1329-1237.
17. Blair, J. M., Zheng, Y., Dunstan, C. R. (in press) RANK ligand. Int. J. Biochem. Cell Biol.
18. Théoleyre, S., Wittrant, Y., Kwan Tat, S., Fortun, Y., Redini, F. and Heymann, D. (2004) The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 15, 457-475.
19. Kwan Tat, S., Padrines, M., Théoleyre, S., Heymann, D. and Fortun, Y. (2004) IL6, RANKL, TNF-alpha/IL1: interrelations in bone resorption pathology. Cytokine Growth Factor Rev. 15, 49-60.
20. Blair, J. M., Zhou, H., Seibel, M. J. and Dunstan, C. (2006) Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat. Clin. Pract. Oncol. 3, 41-49.
21. Rogers, A. and Eastell, R. (2005) Circulating osteoprotegerin and receptor activator of nuclear factor κB ligand: clinical utility in metabolic bone disease assessment. J. Clin. Endocr. Metab. 90, 6323-6331.
22. Walsh, M. C., Kim, N., Kadono, Y., Rho, J., Lee, S. Y., Lorenzo, J. and Choi, Y. (2006) Osteoimmunology: interplay between the immune system and bone metabolism. Annu. Rev. Immunol. 24, 33-63.
23. Kiechl, S., Werner, P., Knoflach, M., Willeit, J. and Schett, G. (2006) The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev. Cardiovasc. Ther. 4, 801-811.
24. Roodman, G. D. (1996) Advances in bone biology: the osteoclast. Endocr. Rev. 17, 308-332.
25. Abu-Amer, Y. (2005) Advances in osteoclast differentiation and function. Curr. Drug Targets Immune Endocr. Metab. Disord. 5, 347-355.
26. Roodman, G. D. (2006) Regulation of osteoclast differentiation. Ann. N. Y. Acad. Sci. 1068, 100-109.
27. Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S. I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., Kanno, T., Murakami, A., Tsuda, E., Morinaga, T. and Higashio, K. (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139, 1329-1337.
28. Tsuda, E., Goto, M., Mochizuki, S., Yano, K., Kobayashi, F., Morinaga, T. and Higashio, K. (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234, 137-142.
29. Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Luthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H. L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T. M., Hill, D., Pattison, W., Campbell, P., Sander, S., Van, G., Tarpley, J., Derby, P., Lee, R., Amgen EST Program and Boyle, W. J. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319.
30. Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., Boyle, W. J. and Simonet, W. S. (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260-1268.
31. Yun, T. J., Tallquist, M. D., Aicher, A., Rafferty, K. L., Marshall, A. J., Moon, J. J., Ewings, M. E., Mohaupt, M., Herring, S.W. and Clarck, E. A. (2001) Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J. Immunol. 166, 1482-1491.
32. Min, H., Morony, S., Sarosi, I., Dunstan, C. R., Capparelli, C., Scully, S., Van, G., Kaufman, S., Kostenuik, P. J., Lacey, D. L., Boyle, W. J. and Simonet, W. S. (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J. Exp. Med. 192, 463-464.
33. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J. and Boyle, W. J. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176.
34. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N. and Suda, T. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci., USA 95, 3597-3602.
35. Wong, B. R., Josien, R., Lee, S. Y., Sauter, B., Li, H. L., Steinman, R. M. and Choi, Y. (1997) TRANCE (tumor necrosis factor TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186, 2075-2080.
36. Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuRose, R. F., Cosman, D. and Galibert, L. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179.
37. Wong, B. H., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Barlett, F. S. 3rd, Frankel, W. N., Lee, S. Y. and Choi, Y. (1997) TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272, 25190-2514.
38. Damay, B. G., Haridas, V., Ni, J., Moore, P. A. and Aggarwal, B. B. (1998) Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK): interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J. Biol. Chem. 273, 20551-20555.
39. Wong, B. R., Josien, R., Lee, S. Y., Vologodskaia, M., Steinman, R. M. and Choi, Y. (1998) The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J. Biol. Chem. 273, 28355-28359.
40. Kong, Y. Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capprelli, C., Li, J., Elliott, R., McCabe, S., Wong, T., Campagnuolo, G., Moran, E., Bogoch, E. R., Van, G., Nguyen, L. T., Ohashi, P. S., Lacey, D. L., Fish, E., Boyle, W. J. and Penninger, J. M. (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304-309.
41. Fata, J. E., Kong, Y. Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R. A., Elliott, R., Scully, S., Voura, E. B., Lacey, D. L., Boyle, W. J., Khokha, R. and Penninger, J. M. (2000) The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41-50.
42. Burgess, T. L., Qian, Y., Kaufman, Ring, B. D., Van, G., Capparelli, M., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C., Hsu, S. and Lacey, D. L. (1999) The ligang for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol. 145, 527-238.
43. Wittrant, Y., Théoleyre, S., Couillaud, S., Dunstan, C., Heymann, D. and Rédini, F. (2004) Relevance of in vitro osteoclastogenesis system to study receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG) biological activities? Exp. Cell Res. 293, 292-301.
44. Wittrant, Y., Théoleyre, S., Couillaud, S., Dunstan, C., Heymann, D. and Rédini, F. (2003) Regulation of osteoclast protease expression by RANKL. Biochem. Biophys. Res. Commun. 310, 774-778.
45. Théoleyre, S., Wittrant, Y., Couillaud, S., Vusio, P., Berreur, M., Dunstan, C., Blanchard, F., Rédini, F. and Heymann, D. (2004) Cellular activity and signalling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of NF-κB ligand and MAPK. Biochim. Biophys. Acta 1644, 1-7.
46. Kwan Tat, S., Padrines, M., Théoleyre, S., Bataglia, S., Heymann, D., Redini, F. and Fortun, Y. (2006) OPG/membranous-RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. Bone 39, 706-715.
47. Nakamichi, Y., Udagawa, N., Kobayashi, Y., Nakamura, M., Yamamoto, Y., Yamashita, T., Mizoguchi, T., Sato, M., Mogi, M., Penninger, J. M. and Takahashi, N. (2007) Osteoprotegerin reduces the serum level of receptor activator of NF-KB ligand derived from osteoblasts. J. Immunol. 178, 192-200.
48. Ikeda, T., Kasai, M., Utsuyama, M. and Hirokawa, K. (2001) Determination of three isoforms of the receptor activator of nuclear factor-κB ligand and their differential expression in bone and thymus. Endocrinology 142, 1418-1426.
49. Suzuki, J., Ikeda, T., Kuroyama, H., Seki, S., Kasai, M., Utsuyama, M., Tatsumi, M., Uematsu, H. and Hirokawa, K. (2004) Regulation of osteoclastogenesis by the three human RANKL isoforms expressed in NIH3T3 cells. Biochem. Biophys. Res. Commun. 314, 1021-1027.
50. Lum, L., Wong, B. R., Josien, R., Becherer, J. D., Erdjument-Bromage, H., Schlondorff, J., Temps, P., Choi, Y. and Blodel, C. P. (1999) Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J. Biol. Chem. 274, 13613-13618.
51. Boissy, P., Lenhard, T. R., Kirgegaard, T., Peschon, J. J., Black, R. A., Delaisse, J. M. and del Carmen Ovejero, M. (2003) An assessment of ADAMs in bone cells: absence of TACE activity prevents osteoclast recruitment and the formation of the marrow cavity in developing long bone. FEBS Lett. 553, 257-261.
52. Hikita, A., Yana,, I., Wakeyama, H., Nakamura, M., Kadono, Y., Oshima, Y., Nakamura, K., Seiki, M. and Tanaka, S. (2006) Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand. J. Biol. Chem. 281, 36846-36855.
53. Chesneau, V. (2001) Catalytic properties of ADAM19. J. Biol. Chem. 278, 22331-22340.
54. Lynch, C. C., Kikosaka, A., Acuff, H. B., Martin, M. D., Kawai, N., Singh, R.K., Varfo-Gogola, T.C., Begtrup, J.L., Peterson, T. E., Fingleton, B., Shirai, T., Matrisian, L.M. and Futakuchi, M. (2005) MMP-7 promotes prostate cancer-induced osteolysis via the solubilisation of RANKL. Cancer Cell 7, 485-496.
55. Ikeda, T., Kasai, M., Kuroyama, H., Seki, S., Utsuyama, M., Hirokawa, K. (2003) Multimerisation of the RANKL isoforms and regulation of osteoclastogenesis. J. Biol. Chem. 278, 47217-47222.
56. Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K., Morinaga, T. and Higashio, K. (1998) RANK is essential signalling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys.Res. Commun. 253, 396-400.
57. Iwamoto, K., Miyamoto, T. , Sawatani, Y., Hosogane, N., Hamaguchi, I., Takami, M., Nomiyama, K., Takagi, K. and Suda, T. (2004) Dimer formation of receptor activator of nuclear factor κB induces incomplete osteoclast formation. Biochem. Biophys. Res. Commun. 325, 229-234.
58. Ito, S., Wakabayashi, K., Ubukota, O., Hayashi, S., Okada, F. and Hata, T. (2002) Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution. J. Biol. Chem. 277, 6631-6636.
59. Kanazawa, K. and Kudo, A. (2005) Self-assembled RANK induces osteoclastogenesis ligand-independently. J. Bone Miner. Res. 20, 2053-2060.
60. Chan, F. K., Chun, H. J., Zheng, L., Siegel, R. M., Bui, K. L. and Lenardo, M. J. (2000) A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288, 2351-2354.
61. Yamaguchi, K., Kinosaki, M., Goto, M., Tsuda, E., Morinaga, T. and Higashio, K. (1998) Characterization of structural domains of human osteoclastogenesis inhibitory factor. J. Biol. Chem. 273, 5117-5123.
62. Takahashi, N., Udagawa, N. and Suda, T. (1999) A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem. Biophys. Res. Commun. 256, 449-455.
63. Schneeweis, L. A., Willard, D. and Milla, M. E. (2005) Functional dissection of osteoprotegerin and its interaction with RANKL. J. Biol. Chem. 280, 41155-41164.
64. Mosheimer, B. A., Kaneider, N. C., Feistritzer, C., Djanani, A. M., Sturn, D. H., Patsch, J. R. and Wiedermann, C. J. (2005) Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J. Clin. Endocrinol. Metab. 90, 2964-2971.
65. Standal, T., Seidel, C., Hjertner,, O., Plesner, T., Sanderson, R. D., Waage, A., Borset, M. and Sundan, A. (2002) Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100, 3002-3007.
66. Théoleyre, S., Kwan Tat, S., Vusio, P., Blanchard, F., Gallagher, J., Ricard-Blum, S., Fortun, Y., Padrines, M., Rédini, F. and Heymann, D. (2006) Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kB ligand (RANKL) and RANK. Biochem. Biophys. Res. Commun. 347, 460-467
67. Stringer, S. E., Forster, M. J., Mulloy, B., Bishop, C. R., Graham, G. J. and Gallagher, J. T. (2002) Characterization of the binding site on heparan sulfate for macrophage inflammatory protein 1a. Blood 100, 1543-1550.
68. Fox, S.W. and Lovibond, A. C. (2005) Current insights into the role of transforming growth factor-beta in bone resorption. Mol. Cell Endocrinol. 243, 19-26.
69. Shinmyouzu, K., Takahashi, T., Ariyoshi, W., Ischimiya, H., Kanzaki, S. and Nishihara, T. (2007) Dermatan sulphate inhibits osteoclast formation by binding to receptor activator of NF-κB ligand. Biochem. Biophys.Res. Commun. 354, 447-452.
70. Bishof, D., Elsawa, S. F., Mantchev, G., Yoon, J., Michels, G. E., Nilson, A., Sutor, S. L., Platt, J. L., Ansell, S. M., von Bulow, G. and Bram, R. J. (2006) Selective activation of TACI by syndecan-2. Blood 107, 3235-3242.
71. Sakurai, D., Hase, H., Kanno, Y., Kojima, H., Okumura, K. and Kobata, T. (2007) TACI regulates Ig1 production by APRIL in collaboration with HSPG. Blood 109, 2961-2967.
72. Hendriks, J., Planelles, L., de Jong-Odding, J., Hardenberg, G., Pals, S. T., Hahne, M., Spaargaren, M. and Medema, J. P. (2005) Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ. 12: 637-648.
73. Emery, J. G., McDonnell, P., Burke, M. B., Deen, L. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eicman, C., DiPrinzio, R., Dodds, R. A., James, I. E., Rosenberg, M., Lee, J. C. and YounG, P. R. (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273, 14363-14367.
74. Cross, S. S., Harrison, R. F., Balasubramanian, S. P., Lippitt, J. M., Evans, C. A., Reed, M.W. and Holen, I. (2006) Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables. J. Clin. Pathol. 59, 716-720.
75. Holen, I. and Shipman, C. M. (2006) Role of osteoprotegerin (OPG) in cancer. Clin. Sci. 110, 279-291.
76. Sandra, F., Hendarmin, L. and Nakamura, S. (2006) Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas. Oral Oncol. 42, 415-420.
77. Van Poznak, C., Cross, S. S., Saggese, M., Hudis, C., Panageas, K. S., Norton, L., Coleman, R. E. and Holen, I. (2006) Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. J. Clin. Pathol. 59, 56-63.
78. Neville-Webbe, H. L., Cross, N. A., Eaton, C. L., Nyambo, R., Evans, C. A., Coleman, R. E. and Holen, I. (2004) Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res. Treat. 86, 269-279.
79. Nyambo, R., Cross, N., Lippitt, J., Holen, I., Bryden, G., Hamdy, F. C. and Eaton, C. L. (2004) Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. J. Bone Miner. Res. 19, 1712-1721.
80. Miyashita, T., Kawakami, A., Nakashima, T., Yamasaki, S., Tamai, M., Tanaka, F., Kamachi, M., Ida, H., Migita, K., Origuchi, T., Nakao, K. and Eguchi, K. (2004) Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin. Exp. Immunol. 137, 430-436.
81. Atkins, G., J., Bouralexis, S., Evdokiou, A., Hays, S., Labrinidis, A., Zannettino, A. C., Haynes, D. R. and Findlay, D. M. (2002) Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone 31, 448-456.
82. Holen, I., Croucher, P. I., Hamdy, F. C. and Eaton, C. L. (2002) Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 62, 1619-1623.
83. Kaifu, T., Nakahara, J., Inui, M., Mishima, K., Momiyama, T., Kaji, M., Sugahara, A., Koito, H., Ujike-Asai, A., Nakamura, A., Kanazawa, K., Tan-Takeuchi, K., Iwasaki, K., Yokoyama, W. M., Kudo, A., Fujiwara, M., Asou, H. and Takai, T. (2003) Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J. Clin. Invest. 111, 323-332.
84. Koga, T. , Inui, M., Inoue, K. , Kim, S. , Suematsu, A., Kobayashi, E. , Iwata, T. , Ohnishi, H. , Matozaki, T. , Kodama, T. , Taniguchi, T. , Takayanagi, H. and Takai, T. (2004) Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428, 758-763.
85. Mocsai, A., Humphrey, M. B., Van Ziffle, J. A., Hu, Y., Burghardt, A., Spusta, S. C., Majumdar, S., Lanier, L.L and Lowell, C. A. (2004) The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc. Natl. Acad. Sci., U.S.A. 101, 6158-6163.
86. Humphrey, M. B., Lanier, L. L. and Nakamura, M. C. (2005) Role of ITAM-containing proteins and their receptors in the immune system and bone. Immunol. Rev. 208, 50-65.
87. Humphrey, M. B., Ogasawara, K., Yao, W., Spusta, S. C., Daws, M. R., Lane, N. E., Lanier, L. L. and Nakamura, M. C. (2004) The signalling adapter protein DAP12 regulates multinucleation during osteoclast development. J. Bone Miner. Res. 19, 224-234.
88. Humphrey, M. B., Daws, M. R., Spusta, S. C., Torchia, J. A., Lanier, L. L., Seaman, W. E. and Nakamura, M. C. (2006) TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function. J. Bone Miner.Res. 21, 237-245.
89. Wittrant, Y., Théoleyre, S., Chipoy, C., Padrines, M., Blanchard, F., Heymann, D. and Rédini, F. (2004) RANKL/RANK/OPG: new therapeutic targets in bone tumors and associated osteolysis. Biochim. Biophys. Acta 1704, 49-57
90. Dougall, W. C. and Chaisson, M. (2006) The RANKL/RANK/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev. 25, 541-549.
91. Jones, D. H., Nakashima T., Sanchez, O. H., Kozieradzki I., Komarova, S. V., Sarosi I., Morony S., Rubin E., Sarao R., Hojilla, C.V., Komnenovic V., Kong, Y. Y., Schreiber M., Dixon, S. J., Sims, S. M., Khokha R., Wada T. and Penninger, J. M. (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440: 692-696.
92. Mori K, Le Goff, B., Charrier, C., Battaglia, S., Heymann, D. and Rédini, F. (2007) DU145 human prostate cancer cells express functional receptor activator of NFκB: new insights in the prostate cancer bone metastasis process. Bone 40, 981-990.
93. Tometsko, M., Armstrong, A., Miller, R., Jones, J., Chaisson, M., Branstetter, D. and Dougall, W. (2004) RANK ligand directly induces osteoclastogenic, angiogenic, chemoattractive and invasive factors on RANK-expressing human cancer cells MDA-MB-231 and PC3. J. Bone Miner. Res. 19: S25
94. Martin, T. J. and Mundy, G. R. (2007) Bone metastasis: can osteoclasts be excluded? Nature 445, E19.
95. Jones, D.H., Nakashima T., Sanchez, O.H., Kozieradzki I., Komarova, S.V., Sarosi I., Morony S., Rubin E., Sarao R., Hojilla, C.V., Komnenovic V., Kong, Y.Y., Schreiber M., Dixon, S.J., Sims, S.M., Khokha R., Wada T. and Penninger, J.M. (2007) Jones et al. reply. Nature 445, E19-E20.
96. Brown J. M., Corey, E., Lee, Z. D., True, L. D., Yun, T. J., Tondravi, M. and Vessella, R. L. (2001) Osteoprotegerin and RANK ligand expression in prostate cancer. Urology 57: 611-616.
97. Zhang J., Dai J., Qi Y., Lin, D.L., Smith P., Strayhorn C., Mizokami A., Fu Z., Westman J. and Keller, E.T. (2001) Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest. 107, 1235-1244.
98. Zhang, J., Dai, J., Yao, Z., Lu, Y., Dougall, W. and Keller, E. T. (2003) Soluble receptor activator of nuclear factor κB Fc diminishes prostate cancer progression in bone. Cancer Res. 63, 7883-7390.
99. Corey E., Brown, L.G., Kiefer, J.A., Quinn, J.E., Pitts, T.E., Blair, J.M. and Vessella, R.L. (2005) Osteoprotegerin in prostate cancer bone metastasis. Cancer Res. 65, 1710-1718.
100. Whang, P.G., Schwarz, E.M., Gamradt, S.C., Dougall, W.C. and Lieberman, J.R. (2005) The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J. Orthop. Res. 23: 1475-1483.
101. Wittrant, Y., Mori, K., Riet, A., Kamijo, A., Heymann, D. and Rédini F (2006) RANKL directly induces bone morphogenetic protein-2 expression in RANK-expression POS-1 osteosarcoma cells. Int. J. Oncol. 28, 261-269
102. Mori, K., Berreur, M., Le Goff, B., Riet, A., Moreau, A., Blanchard, F., Chevalier, C., Guisle-Marsollier, I., Léger, J., Gouin, F., Rédini, F. and Heymann, D. (2007) Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa, B. J. Pathol. 211, 555-562.
103. Pearse, R. N., Sordillo, E. M., Yaccoby, S., Wong, B. R., Liau, D. F., Colman, N., Michaeli, J., Epstein, J. and Choi, Y. (2001) Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl. Acad. Sci. USA 98, 1581-1586.
104. Vanderkerken, K., De Leenheer, E., Shipman, C., Asosingh, K., Willems, A., Van Camp, B. and Croucher, P. (2003) Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res. 63, 287-289.
105. Brown, J. M., Vessella, R. L., Kostenuik, P. J., Dunstan, C. R., Lange, P. H. and Corey, E. (2001) Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin. Cancer Res. 7, 2977-2983.
106. Grimaud, E., Soubigou, L., Couillaud, S., Coipeau, P., Moreau, A., Passuti, N., Gouin, F., Rédini, F. and Heymann, D. (2003) Receptor activator of NF-kB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am. J. Pathol. 163, 2021-2031.
107. Giuliani, N., Bataille, R., Mancini, C., Lazzaretti, M. and Barille, S. (2001) Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98, 3527-3533.
108. Voskaridou, E. and Terpos E (2005) Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3. Eur. J. Haematol. 74, 359-361.
109. Alvarez, L., Peris, P., Guanabens, N., Vidal, S., Ros, I., Pons, F., Filella, X., Monegal, A., Munoz-Gomez, J. and Ballesta, A. M. (2003) Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum. 48, 824-828.
110. Dobnig, H., Hofbauer, L. C., Viereck, C., Obermayer-Pietsch, B. and Fahrleitner-Pammer A . (2006) Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporosis Int. 17, 693-703.
111. Chen, G., Sircar, K., Aprikian, A., Potti, A., Goltzman, D. and Rabbani SA (2006) Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107, 289-298.
112. Milkosch, P., Igerc, I., Kidlacek, S., Woloszczuk, W., Gallowithsch, H. J., Kresnik, E., Stettner, H., Grimm, G., Lind, P. and Pietschmann, P. (2006) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin in men with thyroid cancer. Eur. J. Clin. Invest. 35, 566-573.
113. Granchi, D., Garaventa, A., Amato, I., Paolucci, P. and Baldini, N. (2006) Plasma levels of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in patients with neuroblastoma. Int. J. Cancer. 119, 146-151.
114. Terpos, E., Szydlo, R., Apperley, J. F., Hatjiharissi, E., Politou, M., Meletis, J., Viniou, N., Yataganas, X., Goldman, J. M. and Rahemtulla, A. (2003) Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102, 1064-1069.
115. D'Amore, M., Fanelli, M., D'Amore, S., Fontana, A. and Minenna, G. (2006) Receptor activator of NF(kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of Apulian postmenopausal women. Panminerva Med. 48, 215-221.
116. Kim, H. R., Kim, H. Y. and Lee, S. H. (2006) Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology 45, 1197-1200.
117. Vanderborght, A., Linsen, L., Thewissen, M., Geusens, P., Raus, J. and Stinissen, P. (2004) Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls. J. Rheumatol. 31, 1483-1490.
118. Veigl, D., Niederlova, J. and Krystufkova, O. (in press). Periprosthetic osteolysis and its association with the molecule RANKL expression. Physiol. Res.
119. Granchi, D., Pellacani, A., Spina, M., Cenni, E., Savarino, L. M., Baldini, N. and Giunti, A. (2006) Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis. J. Bone Joint Surg. Am. 88, 1501-1509.
120. Abdallah, B. M., Stilgren, L. S., Nissen, N., Kassem, M., Jorgensen, H. R. and Abrahamsen, B. (2005) Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures. Calcif. Tissue Int. 76, 90-97.
121. Martini, G., Gennari, L., Merlotti , D., Salvadori, S., Franci, M. B., Campagna, S., Avanzati, A., De Paola, V., Vallegi, F. and Nuti R (2007). Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Bone 40, 457-463.
122. Terpos, E., Politou, M., Szydlo, R., Nadal, E., Avery, S., Olavarria, E., Kanfer, E., Goldman, J. M., Apperley, J. F. and Rahemtulla, A. (2004). Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia 18, 1420-1426.
123. Di Carlo, C., Tommaselli, G. A., Gargano, V., Sammartino, A., Bifulco, G., Tauchmanova, L., Colao, A. and Nappi, C. (2007) Effects of estrogen-progestin therapy on serum levels of RANKL, osteoprotegerin, osteocalcin, leptin, and ghrelin in postmenopausal women. Menopause 14, 38-44.
124. Dovio, A., Data, V. and Angeli, A. (2005) Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice? J. Endocrinol. Invest. 28, 14-22.
125. Humphrey, E. L. Williams, J. H. H., Davie, M. W. J. and Marshall, M. J. (2006) Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone 38, 652-661.
126. Palmqvist, P., Lundberg, P., Persson, E., Johansson, A., Lundgren, I., Lie, A., Conaway, H. H. and Lerner, U. H. (2005) Inhibition of hormone and cytokine stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased OPG and decreased RANKL and RANK in a STAT6 dependent pathway. J. Biol. Chem. 281, 2414-2419.
127. Kaji, H., Kanatani, M., Sugimoto, T. and Chihara, K. (2005) Statins modulate the levels of osteoprotegerin/receptor activator activatot of NFkappa B ligand mRNA in mouse bone-cell cultures. Horm. Metab. Res. 37, 589-592.
128. Li, Y., Kucuk, O., Hussain, M., Abrams, J., Cher, M. L. and Sarkar, F. H. (2006) Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res. 66, 4816-4825.
129. Kiviranta, R., Morko, J., Alatalo, S. L., NicAmhlaoibh, R., Risteli, J., Laitala-Leinonen, T. and Vuorio, E. (2005) Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone 36, 159-172.
130. Li, J., Sarosi, I., Yan, X. Q., Morony, S., Capparelli, C., Tan, H. L., McCabe, S., Elliott, R., Scully, S., Van, G., Kaufman, S., Juan, S. C., Sun, Y., Tarpley, J., Martin, L., Christensen, K., McCabe, J., Kostenuik, P., Hsu, H., Fletcher, F., Dunstan, C. R., Lacey, D. L. and Boyle, W. J. (2000) RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci., USA 97, 1566-1571.
131. Lee, H. W., Kim, B. S., Kim, H. J., Lee, C. W., Yoo, H. J., Kim, J. B. and Yoon, S. (2005) Upregulation of receptor activator of nuclear factor-kappaB ligand expression in the thymic subcapsular, paraseptal, perivascular, and medullary epithelial cells during thymus regeneration. Histochem. Cell Biol. 123, 491-500.
132. Walsh, M. C., Kim, N., Kadono, Y., Rho, J., Lee, S. Y., Lorenzo, J. and Choi, Y. (2006) Osteoimmunology: interplay between the immune system and bone metabolism. Annu. Rev. Immunol. 24, 33-63.
133. Mosheimer, B. A., Kaneider, N. C., Feistritzer, C., Sturn, D. H. and Wiedermann, C. J. (2004) Expression and function of RANK in human monocyte chemotaxis. Arthritis Rheum. 50, 2309-2316.
134. Breuil, V., Schmid-Antomarchi, H., Schmid-Alliana, A., Rezzonico, R., Euller-Ziegler, L. and Rossi, B. (2003) The receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) is a new chemotactic factor for human monocytes. FASEB J. 17, 1751-1753.
135. Henrisksen, K., Karsdal, M., Delaisse, J. M. and Engsig, M. T. (2003) RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism. J. Biol. Chem. 278, 48745-48753.
136. Lee, S. K. and Lorenzo, J. (2006) Cytokines regulating osteoclast formation and function. Curr. Opin. Rheumatol. 18, 411-418.
137. Kwak, H. B., Lee, S. W., Jin, H. M., Ha, H., Lee, S. H., Takeshita, S., Tanaka, S., Kim, H. M., Kim, H. H. and Lee, Z. H. (2005) Monokine induced by interferon-gamma is induced by receptor activator of nuclear factor kappa B ligand and is involved in osteoclast adhesion and migration. Blood 105, 2963-2969.
138. Nakamura, E. S., Koizumi, K., Kobayashi, M., Saitoh, Y., Arita, Y., Nakayama, Y., Sakurai, H., Yoshie, O. and Saiki, I. (2006) RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4. Clin. Exp. Metastasis. 23, 9-18.
139. Kim, M. S., Day, C. J., and Morrison, N. A. (2005) MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation J. Biol. Chem. 280, 16163-16169.
140. Secchiero, P., Corallini, F., Barbarotto, E., Melloni, E., di Iasio, M. G., Tiribellu, M. and Zauli, G. (2006) Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells. J. Cell Physiol. 207, 158-164.
141. Terpos, E., Politou, M., Viniou, N. and Rahemtulla, A. (2005) Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma. Leuk. Lymphoma 46, 1699-1707.
142. Bendre, M., Gaddy, D., Nicholas, R. W. and Suva, L. J. (2003) Breast cancer metastasis to bone: it is not all about PTHrP. Clin. Orthop. Relat. Res. 415 Suppl: S39-S45.
143. Seshasayee, D., Wang, H., Lee, W. P., Gribling, P., Ross, J., Wan Bruggen, N., Carano, R. and Grewal, I. S. (2004). A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. J. Biol. Chem. 279, 30202-30209.
144. Park, H. J., Park, O. J. and Shin, J. (2005) Receptor activator of NF-kappaB ligand enhances the activity of macrophages as antigen presenting cell. Exp. Mol. Med. 37, 524-532.
145. Ali, A. S., Lax, A.S, Lijestrom, M., Paakkari, I., Ashammakhi, N., Kovanen, P. T. and Konttinen, Y. T. (2006) Mast cells in atherosclerosis as a source of the cytokine RANKL. Clin. Chem. Lab. Med. 44, 672-674.
146. Maitz, P., Kandler, B., Fischer, M. B., Watzek, G. and Gruber, R. (2006) Activated platelets retain their potential to induce osteoclast-like cell formation in murine bone marrow cultures. Platelets 17, 477-483
147. Kawai, T., Matsuyama, T., Hosokawa, Y., Makihira, S., Ski, M., Karimbux, N. Y., Gooncalves, N. Y., Goncalves, R. B., Valcerde, P., Dibart, S., Li, Y. P., Miranda, L. A., Ernst, C. W., Izumi, Y. and Taubman, M. A. (2006) B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am. J. Pathol. 169, 987-998.
148. Kotake, S., Udagawa,, N., Hakoda, M., Mogi, M., Yano, K., Tsuda, E., Takahashi, K., Furuya, T., Ishiyama, S., Kim, K. J., Saito, S., Nishikawa, N., Togari, A., Tomastsu, T., Suda, T. and Kamatani, N. ( 2001) Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 44, 1003-1012.
149. Schett, G., Hayer, S., Zwerina, J., Redlich, K., and Smolen, J. S. (2005) Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat. Clin. Pract. Rheumatol. 1, 47-54.
150. Masui, T., Sakano, S., Hasegawa, Y., Warashina, H. and Ishiguro, N. (2005) Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles. Biomaterials 26, 1695-1702.
151. Maruyama, K., Takada, Y., Ray, N., Kishimoto, Y., Penninger, J. M., Yasuda, H. and Matsuo, K. (2006) Receptor activator of NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice. J. Immunol. 177, 3799-3805.
152. Ashcroft, A. J., Cruickshank, S. M., Croucher, P. I., Perry, M. J., Rollinson, S., Lippit, J. M., Child, J. A., Dunstan, C., Felsburg, P. J., Morgan, G. J. and Carding, S. R. (2003) Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity19, 849-861.
153. Green, E. A., Choi, Y. and Flavell, R. A. (2002) Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 16, 183-191.
154. Loser, K., Mehling, A., Loeser, S., Apelt, J., Kuhn, A., Grabbe, S., Schwarz, T., Penninger, J. M. and Beissert, S. (2006) Epidermal RANKL controls regulatory T-cell numbers via activation of dentritic cells. Nat. Med. 12, 1372-1379.
155. Schoppet, M., Henser, S., Ruppert, V., Stubig, T., Al-Fakhri, N., Maisch, B. and Hofbauer, L. C. (2007) Osteoprotegerin expression in dendritic cells increases with maturation and is NF-kappaB-dependent. J. Cell. Biochem. 100, 1430-1439.
156. Yun, T. J., Tallquist, M. D., Aicher, A., Rafferty, K. L., Marshall, A. J., Moon, J. J., Ewings, M. E., Mohaupt, M., Herring, S.W. and Clark, E. A. (2001) Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J. Immunol. 166, 1482-1491.
157. Grevic, D. V., Lukic, K., Kovacic, N., Ivcevic, S., Katavic, V. and Marusic, A. (2006) Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos. Clin. Exp. Immunol. 146, 46-58.
158. Zannettino, A. C., Holding, C. A., Diamond, P., Atkins, G. J., Kostakis, P., Farrugia, A., Gamble, J., To, L. B., Findlay, D. M., Haynes, D. R. (2005) Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J. Cell Physiol. 204, 714-723.
159. Collin-Osdoby, P. (2004) Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ. Res. 95, 1046-1057.
160. Collin-Osdoby, P., Rothe, L., Anderson, F., Nelson, M., Maloney, W. and Osdoby, P. (2001) Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J. Biol. Chem. 276, 20659-20672.
161. Kaden, J. J., Bickelhaupt, S., Grobholz, R., Haase, K. K., Sarikoc, A., Kilic, R., Brueckmann, M., Lang, S., Zahn, I., Vahl, C., Hagl, S., Dempfle, C. E. and Borggrefe, M. (2004) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J. Mol. Cell Cardiol. 36, 57-66.
162. Kindle, L., Rothe, L., Kriss, M., Osdoby, P. and Collin-Osdoby, P. (2006) Human microvascular endothelial cell activation by IL-1 and TNF-alpha stimulates the adhesion and transendothelial migration of circulating human CD14+ monocytes that develop with RANKL into functional osteoclasts. J. Bone Miner. Res. 21, 193-206.
163. Olesen, P., Ledet, T. and Rasmussen, L. M. (2005) Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 48, 561-568.
164. Olesen, P., Nguyen, K., Wogensen, L., Ledet, T. and Rasmussen, L. M. (2007) Calcification of human vascular smooth muscle cells: associations with osteoprotegerin expression and acceleration by high-dose insulin. Am. J. Physiol. Heart Circ. Physiol. 292, H1058-H1064.
165. Anand, D. V., Lahiri, A., Lim, E., Hopkins, D. and Corder, R. (2006) The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J. Am. Coll. Cardiol. 47, 1850-1857.
166. Vik, A., Mathiesen, E. B., Noto, A. T., Sveinbjornsson, B., Brox, J. and Hansen, J. B. (2007) Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. Atherosclerosis 191, 128-134.
167. Ziegler, S., Kudlacek, S., Luger, A. and Minar, E. (2005) Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 182, 175-180.
168. Pritzker, L. B., Scatena, M. and Giachelli, C. M. (2004) The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol. Biol. Cell. 15, 2834-2841.
169. Malyankar, U. M., Scatena, M., Suchland, K. L., Yun, T. J., Clark, E. A. and Giachelli, C. M. (2000) Osteoprotegerin is an alpha vbeta 3-induced, NF-kappaB-dependent survival factor for endothelial cells. J. Biol. Chem. 275, 20959-20962.
170. Scatena, M., Giachelli, C. (2002) The αvβ3 integrin, NF-κB, osteoprotegerin endothelial cell survival pathway. Trends Cardiovasc. Med. 12, 83-88.
171. Kobayashi-Sakamoto, M., Hirose, K., Nishikata, M., Isogai, E. and Chiba, I. (2006) Osteoprotegerin protects endothelial cells against apoptotic cell death induced by Porphyromonas gingivalis cysteine proteinases. FEMS Microbiol. Lett. 264, 238-245.
172. Kobayashi-Sakamoto, M., Hirose, K., Isogai, E. and Chiba, I. (2004) NF-kappaB-dependent induction of osteoprotegerin by Porphyromonas gingivalis in endothelial cells. Biochem. Biophys. Res. Commun. 315, 107-112.
173. Cross, S. S., Yang, Z., Brown, N. J., Balasubramanian, S. P., Evans, C. A., Woodward, J. K., Neville-Webbe, H. L., Lippitt, J. M., Reed, M.W., Coleman, R. E. and Holen, I. (2006) Osteoprotegerin (OPG) - a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int. J. Cancer 118, 1901-1908.
174. Kim, Y. M., Kim, Y. M., Lee, Y. M., Kim, H. S., Kim, J. D., Choi, Y., Kim, K.W., Lee, S. Y. and Kwon, Y. G. (2002) TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells. J. Biol. Chem. 277, 6799-6805.
175. Min, J. K., Kim, Y. M., Kim, Y. M., Kim, E. C., Gho, Y. S., Kang, I. J., Lee, S. Y., Kong, Y. Y. and Kwon, Y. G. (2003) Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells: concomitant increase of angiogenic responses to RANK ligand. J. Biol. Chem. 278, 39548-39557.
176. Kim, H. H., Shin, H. S., Kwak, H. J., Ahn, K. Y., Kim, J. H., Lee, H. J., Lee, M. S., Lee, Z. H. and Koh, G. Y. (2003) RANKL regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. FASEB J. 17, 2163-2165.
177. Min, J. K., Cho, Y. L., Choi, J. H., Kim, Y., Kim, J. H., Yu, Y. S., Rho, J., Mochizuki, N., Kim, Y. M., Oh, G. T. and Kwon, Y. G.. (2007) Receptor activator of nuclear factor-kB ligand increases vascular permeability: impaired permeability and angiogenesis in eNOS-deficient mice. Blood 109, 1496-1502.
178. Zhang, J., Fu, M., Myles, D., Zhu, X., Du, J., Cao, X. and Chen, Y. E. (2002) PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett. 521, 180-184.
179. Yao, S., Liu, D., Pan, F. and Wise, G. E. (2006) Effect of vascular endothelial growth factor on RANK gene expression in osteoclast precursors and on osteoclastogenesis. Arch. Oral Biol. 51, 596-602.
180. Asagiri, M. and Takayanagi, H. (2007) The molecular understanding of osteoclast differentiation. Bone 40, 251-264.
181. Wada, T., Nakashima, T., Hiroshi, N. and Penninger, J. (2006) RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol. Med. 12, 17-25.
182. Body, J. J., Facon, T., Coleman, R. E., Lipton, A., Geurs, F., Fan, M., Holloway, D., Peterson, M. C. and Bekker, P. J. (2006) A study of the biological receptor activator of nuclear factor-kappa B ligand inhibitor, Denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin. Cancer Res. 12, 1221-1228.
183. Kim, H. K.W., Morgan-Bagley, S. and Kostenuik, P. (2006) RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis. J. Bone Miner. Res. 21, 1946-1954.
184. Feeley, B. T., Liu, N. Q., Conduah, A. H., Krenek, L., Roth, K., Dougall, W. C., Huard, J., Dubinett, S. and Lieberman, J. R. (2006) Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and rank: Fc administration. J. Bone Miner. Res. 21, 1571-1580.
185. Heymann, D., Ory, B., Blanchard, F., Heymann, M. F., Coipeau, P., Charrier, C., Couillaud, S., Thiry, J. P., Gouin, F. and Rédini, F. (2005) Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 37, 74-86.
186. Cheng, X., Kinosaki, M., Takami, M., Choi, Y., Zhang, H. and Murali, R. (2004) Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. J. Biol. Chem. 279, 8269-8277.
187. Heath, D. J., Vanderkerken, K., Cheng, X., Gallagher, O., Prideaux, M., Murali, R. and Croucher, P. I. (2007) An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res. 67, 202-208.
188. Aoki, K., Saito, H., Itzstein, C., Ishiguro, M., Shibata, T., Blanque, R., Mian, A. H., Takahashi, M., Suzuki, Y., Yoshimatsu, M., Yamaguchi, A., Deprez, P., Mollat, P., Murali, R., Ohya, K., Horne, W. C. and Baron, R. (2006) A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. J. Clin. Invest. 116, 1525-1534.
189. Heymann, D., Fortun, Y., Rédini, F. and Padrines, M. (2005) Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools to the standard bisphosphonates. Drug Discov. Today 10, 242-247.
190. Xing, L., Bushnell, T. P., Carlson, L., Tai, Z., Tondravi, M., Siebenlist, U., Young, F. and Boyce, B. F. (2002) NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J. Bone Miner. Res. 17, 1200-10
191. Xing, L., Carlson, L., Story, B., Tai, Z., Keng, P., Siebenlist, U. and Boyce, B. F. (2003) Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. J. Bone Miner. Res. 18, 260-269.
192. Chen, T. and Feng, X. (2006) Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors. Assay Drug Dev. Technol. 4, 473-492.
193. Jimi, E. and Ghish, S. (2005) Role of nuclear factor-kappa B in the immune system and bone. Immunol. Rev. 208, 80-87.
194. Iotsova, V., Caamano, J., Loy, J., Yang, Y., Lewin, A. and Bravo, R. (1997) Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat. Med. 3, 1285-1289.
195. Eguchi, J., Koshino, T., Takagi, T., Hayashi, T. and Saito, T. (2002) NF-kappa B and I-kappa B overexpression in articular chondrocytes with progression of type II collagen-induced arthritis in DBA/1 mouse knees. Clin. Exp. Rheumatol. 20, 647-652.
196. Cho, M. L., Kang, J. W., Moon, Y. M., Nam, H. J., Jhun, J. Y., Heo, S. B., Jin, H. T., Min, S. Y., Ju, J. H., Park, K. S., Cho, Y. G., Yoon, C. H., Park, S. H., Sung, Y. C. and Kim, H. Y. (2006) STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J. Immunol. 176, 5652-5661.
197. Amos, N., Lauder, S., Evans, A., Feldmann, M. and Bondeson, J. (2006) Adenoviral gene transfer into osteoarthritis synovial cells using the endogenous inhibitor IkappaBalpha reveals that most, but not all, inflammatory and destructive mediators are NFkappaB dependent. Rheumatology 45, 1201-1209.
198. Okamoto, T. (2006) NF-kappaB and rheumatic diseases. Endocr. Metab. Immune Disord. Drug Targets 6, 359-372.
199. Park, B. K., Zhang, H., Zeng, Q., Dai, J., Keller, E. T., Giordano, T., Gu, K., Shah, V., Zarbo, R. J., McCauley, L., Shi, S., Chen, S. and Wang, C. Y. (2007). NF-kB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat. Med. 13, 62-69.
200. Clohisy,, J. C., Hirayama, T., Frazier, E., Han, S. K. and Abu-Amer, Y. (2004) NF-κB signaling blockade abolishes implant particle-induced osteoclastogenesis. J. Orthop. Res. 22, 13-20.
201. Clohisy,, J. C., Roy, B. C., Biondo, C., Frazier, E., Willis, D., Teitelbaum, S. L. and Abu-Amer, Y. (2003) Direct inhibition of NF-kappa B blocks bone erosion associated with inflammatory arthritis. J. Immunol. 171, 5547-5553
202. Kawamura, I., Morishita, R., Tomita, N., Lacey, E., Aketa, M., Tsujimoto, S., Manda, T., Tomoi, M., Kida, I., Higaki, J., Kaneda, Y., Shimomura, K. and Ogihara, T. (1999) Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model. Gene Ther. 6, 91-97.
203. Penolazzi, L., Borgatti, M., Lambertini, E., Mischiati, C., Finotti, A., Romanelli, A., Saviano, M., Pedone, C., Piva, R. and Gambari, R. (2004) Peptide nucleic acid-DNA decoy chimeras targeting NF-kappaB transcription factors: induction of apoptosis in human primary osteoclasts. Int. J. Mol. Med. 14, 145-152.
204. Penolazzi, L., Lambertini, E., Borgatti, M., Piva, R., Cozzani, M., Giovannini, I., Naccari, R., Siciliani, G. and Gambari, R. (2003) Decoy oligodeoxynucleotides targeting NF-kappaB transcription factors: induction of apoptosis in human primary osteoclasts. Biochem. Pharmacol. 66, 1189-1198.
205. Suzuki, Y., Sgiyama C, Ohno, O. and Umezawa, K. (2004). Preparation and biological activities of optically active dehydroxymethylepoxyquinomycin, a novel NF-kB inhibitor. Tetrahedron 60, 7061-7066.
206. Takatsuna, H., Asgiri, M., Kubota, T., Oka, K., Osada, T., Sugiyama, C., Saito, H., Aoki, K., Ohya, K., Takayanagi, H. and Umezawa, K. (2005) Inhibition of RANKL-induced osteoclastogenesis by ( -)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. J. Bone Miner. Res. 20, 653-662.
207. Ye, H., Arron, J. R., Lamothe, B., Cirilli, M., Kobayashi, T., Shevde, N. K., Segal, D., Dzivenu, O. K., Vologodskaia, M., Yim, M., Du, K., Singh, S., Pike, J. W., Darnay, B. G., Choi, Y. and Wu, H. (2002) Distinct molecular mechanism for initiating TRAF6 signalling. Nature 418, 443-447.